1. Home
  2. HURA vs LOGC Comparison

HURA vs LOGC Comparison

Compare HURA & LOGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • LOGC
  • Stock Information
  • Founded
  • HURA 2009
  • LOGC 2010
  • Country
  • HURA United States
  • LOGC United States
  • Employees
  • HURA N/A
  • LOGC N/A
  • Industry
  • HURA
  • LOGC Catalog/Specialty Distribution
  • Sector
  • HURA
  • LOGC Consumer Discretionary
  • Exchange
  • HURA Nasdaq
  • LOGC Nasdaq
  • Market Cap
  • HURA 193.8M
  • LOGC 167.6M
  • IPO Year
  • HURA N/A
  • LOGC 2020
  • Fundamental
  • Price
  • HURA $3.35
  • LOGC $6.92
  • Analyst Decision
  • HURA
  • LOGC
  • Analyst Count
  • HURA 0
  • LOGC 0
  • Target Price
  • HURA N/A
  • LOGC N/A
  • AVG Volume (30 Days)
  • HURA 77.7K
  • LOGC 305.6K
  • Earning Date
  • HURA 11-14-2024
  • LOGC 11-07-2024
  • Dividend Yield
  • HURA N/A
  • LOGC N/A
  • EPS Growth
  • HURA N/A
  • LOGC N/A
  • EPS
  • HURA N/A
  • LOGC N/A
  • Revenue
  • HURA N/A
  • LOGC $96,000,000.00
  • Revenue This Year
  • HURA N/A
  • LOGC N/A
  • Revenue Next Year
  • HURA N/A
  • LOGC $422.91
  • P/E Ratio
  • HURA N/A
  • LOGC N/A
  • Revenue Growth
  • HURA N/A
  • LOGC N/A
  • 52 Week Low
  • HURA $2.84
  • LOGC $4.01
  • 52 Week High
  • HURA $17.36
  • LOGC $7.11
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • LOGC 63.79
  • Support Level
  • HURA N/A
  • LOGC $6.19
  • Resistance Level
  • HURA N/A
  • LOGC $7.11
  • Average True Range (ATR)
  • HURA 0.00
  • LOGC 0.29
  • MACD
  • HURA 0.00
  • LOGC 0.02
  • Stochastic Oscillator
  • HURA 0.00
  • LOGC 75.00

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About LOGC ContextLogic Inc.

ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives a majority of its revenue from Europe and also has a presence in North America; South America, and other countries.

Share on Social Networks: